NICE recommends non‑hormonal therapy for moderate to severe vasomotor symptoms More: NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats Source: News
read more
BE BOLD trial shows bimekizumab outperforms risankizumab at Week 16 More: UCB reports superiority of bimekizumab in psoriatic arthritis study Source: News
read moreSandoz is committing even further to its biosimilar business with plans to launch a dedicated unit that will operate separately from the company’s remaining small molecule generics division. More: Sandoz to set up standalone biosimilars unit as it eyes upcoming
read moreIn his second year as CEO, AbbVie’s Robert Michael received a $32.5 million pay package, a hefty raise from his 2024 pay of $18.5 million. More: AbbVie's Robert Michael earns hefty pay bump to .5M in 2nd year as CEO
read morePharmas’ direct drug sale platforms could be the key to bridging the sizable gap between patients’ awareness of certain medications and actual prescription numbers, a new survey suggests. More: Patients want price transparency, e-commerce experience from pharma DTP platforms: survey
read moreLeerink Partners called the departure of BioNTech CEO Uğur Şahin and his wife, and CMO Özlem Türeci, to establish a new startup a “logical step.” But the analysts also questioned whether the German company can “effectively iterate and expand their
read more© 1994 - 2026 B.M. Pharmaceuticals